Understand the source comparison
KPV vs Conventional Hashimoto's Treatments — Comparison
Levothyroxine (synthetic T4) Replaces deficient thyroid hormone Gold standard. Phase IV, decades of data 25–200 g daily, titrated to TSH Does not address autoimmune process. Only replaces hormone Standard of care for hypothyroidism; does not reduce antibodies
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Levothyroxine (synthetic T4)
- Replaces deficient thyroid hormone
- Gold standard. Phase IV, decades of data
- 25–200 μg daily, titrated to TSH
- Does not address autoimmune process. Only replaces hormone
- Standard of care for hypothyroidism; does not reduce antibodies or slow disease progression
- KPV peptide
- Inhibits NF-κB translocation, reducing inflammatory cytokine production
- Preclinical (in-vitro, animal models). No Phase III human trials for Hashimoto's
- 500–2000 μg subcutaneous or intranasal, frequency undefined
- Lacks human dosing validation; no FDA approval for thyroid indications
- Mechanistically promising but clinically unproven; appropriate only in research or highly informed contexts
- Selenium supplementation
- Cofactor for glutathione peroxidase, reduces oxidative stress in thyroid tissue
- Meta-analysis of RCTs shows modest antibody reduction (10–20%)
- 200 μg daily
- Effect size small; does not halt disease
- Evidence-based adjunct with limited but measurable benefit
- Low-dose naltrexone (LDN)
- Modulates immune response via opioid receptor pathways; mechanism in autoimmunity unclear
- Case series and small trials; no large RCTs
- 1.5–4.5 mg nightly
- Off-label; inconsistent results; mechanism poorly understood
- Used by functional medicine practitioners; lacks robust trial data